- *Epidemiologic conditions of the sites*: Ongoing [[STH]] deworming activities
-
- ## Objetivos y logros de los proyectos STOP previos (en background)
- Qualification at EMA for art. 58
- Safety of IVM up to 600μg/kg alone and in coformulation with albendazole
@ -47,6 +46,9 @@
- The access plan is being developed
- Integration across programs (these results have implications beyond STH)
- Progress has been achieved through public-private partnerships but more partners are needed to reach the ultimate goal.
- Project duration (36 months); cuando empieza y cuando acaba (20 junio 2026)
- ## Basic facts del proyecto
-
- ## Investigadores principales de cada uno de los partners
- ## Abstract del proyecto
- [[Soil-Transmitted Helminths]] (STH) remain a significant public health problem with recognized obstacles for control and elimination with the current benzimidazole regimens in [[Mass Drug Administration]] (MDA) campaigns. Renewed targets from [[WHO]] for 2030 include elimination of [[STH]] morbidity in pre-school and school age children (PSAC & SAC), increased country governance and financial support and a strongyloidiasis control program; 2030 has also been targeted by [[WHO]] for controlling NTDs to attain the Sustainable Development Goals.
@ -56,6 +58,5 @@
This [[project]], [[STOP2030]], seeks to complement the results of the safety and efficacy trial with a field-based safety and effectiveness clinical study, acceptability studies in [[Ghana]] and [[Kenya]], modelling and cost-effectiveness exercises. The resulting information will be consolidated to build a multidisciplinary package for policy making and [[WHO]] guidance with the support of advocacy and communication activities to reach stakeholders and maximize the exploitation and impact of the [[FDC]] for [[STH]] control and elimination.
The Consortium assembled to execute the [[STOP2030]] proposal combines expertise in complementary fields [[from]] program assessment and implementation through Ministries of [[Health]] in sub Saharan African countries, advocacy, state of the art technology, leadership in clinical research and a pharma that has shown commitment for generating access to drugs against NTDs and has recently obtained [[WHO]] prequalification for generic ivermectin #INFO
- Project duration (36 months); cuando empieza y cuando acaba (20 junio 2026)
Borja Robert
11 months ago